BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 17519902)

  • 1. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
    Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
    Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
    Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries.
    Mahar PJ; Rana JA; Kennedy CS; Christopher NC
    Pediatr Emerg Care; 2007 Aug; 23(8):544-8. PubMed ID: 17726413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
    J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.
    Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; Mangione S
    J Pain Symptom Manage; 2008 Mar; 35(3):307-13. PubMed ID: 18178368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
    Landy SH
    Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
    Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
    Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.
    Lichtor JL; Sevarino FB; Joshi GP; Busch MA; Nordbrock E; Ginsberg B
    Anesth Analg; 1999 Sep; 89(3):732-8. PubMed ID: 10475315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
    Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
    J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.